One of the most important questions in obesity medicine is whether losing weight with newer medications translates into better long-term cardiovascular health. An August 2026 analysis of three-year SURMOUNT-1 data provides encouraging evidence for tirzepatide – but the distinction between predicted risk and actual cardiovascular events is essential.
What researchers studied
SURMOUNT-1 was a randomized clinical trial of tirzepatide in adults with obesity or overweight without type 2 diabetes. The new post hoc analysis focused on participants with prediabetes and no pre-existing cardiovascular disease and used the Framingham Heart Study equation to estimate each participant’s predicted 10-year cardiovascular disease risk.
The analysis included 962 participants who had the information required to calculate cardiovascular-risk scores over time. Researchers evaluated predicted risk at week 72 and again at week 176 – approximately 3 years.
What happened to predicted cardiovascular risk?
At week 72, all three tirzepatide doses were associated with lower predicted 10-year cardiovascular risk, while predicted risk increased in the placebo group. At week 176, the separation persisted. For example, the 15-mg tirzepatide group had a predicted absolute risk reduction of 1.31 percentage points from baseline, while the placebo group’s predicted risk increased by 3.84 percentage points. The model-derived hazard ratio for the 15-mg dose at week 176 was 0.62.
The pattern was dose-related and was seen across the tirzepatide doses evaluated. These modeled changes likely reflect improvements in several inputs that influence cardiovascular risk, including body weight and cardiometabolic risk factors.
Predicted risk is not the same as fewer heart attacks
This is the most important limitation for patients to understand. The study did not demonstrate that tirzepatide reduced heart attacks, strokes, or cardiovascular deaths by the percentages generated by the risk model. The investigators calculated predicted 10-year risk using the Framingham equation. Therefore, the hazard ratios reported in this analysis are model-derived estimates, not hazard ratios from observed cardiovascular events in SURMOUNT-1.
That does not make the findings unimportant. Risk calculators combine established cardiovascular risk factors and can help estimate whether a patient’s overall profile is moving in a favorable direction. But an improvement in a risk score should not be described as proof of an equivalent reduction in clinical events.
Why three-year data matter
Many obesity-drug studies report outcomes after roughly one year to 18 months. The week-176 analysis is valuable because obesity is a chronic disease and cardiovascular prevention is a long-term goal. A treatment that improves risk factors briefly but cannot be maintained would have less clinical value than one whose benefits persist with ongoing therapy.
A broader definition of successful weight management
For patients, the study reinforces an important shift in how obesity treatment should be evaluated. The goal is not simply to achieve the lowest possible weight. It is to reduce excess adiposity while improving health and maintaining treatment safely over time.
That may mean monitoring blood pressure, lipids, glucose or A1c when appropriate, sleep apnea, physical function, nutrition, and other obesity-related complications in addition to body weight. It also means planning for maintenance rather than assuming treatment ends when a target weight is reached.
BeLite Clinical Perspective
The three-year SURMOUNT-1 analysis is encouraging because the predicted cardiovascular-risk improvement persisted during long-term tirzepatide treatment. The scientifically accurate message, however, is that tirzepatide improved a validated model of predicted cardiovascular risk in this population. Whether and by how much tirzepatide prevents cardiovascular events in people with obesity requires cardiovascular-outcomes evidence designed to answer that question.
Frequently Asked Questions
Does tirzepatide prevent heart attacks?
This particular study does not prove that. It found improvement in a model of predicted 10-year cardiovascular disease risk. It did not measure a reduction in actual heart attacks, strokes, or cardiovascular deaths as its outcome.
What does “predicted 10-year cardiovascular risk” mean?
It is an estimate generated from a validated risk equation using established cardiovascular risk factors. In this analysis, investigators used the Framingham Heart Study equation. A lower predicted risk suggests that the overall risk-factor profile improved, but it is not the same as observing fewer cardiovascular events in a clinical outcomes trial.
How long were participants followed in this analysis?
Researchers evaluated predicted cardiovascular risk at week 72 and again at week 176, which is approximately three years. The analysis included 962 SURMOUNT-1 participants with prediabetes and no pre-existing cardiovascular disease who had the data needed for the risk calculations.
Why is the three-year result important?
Obesity is a chronic disease, so durability matters. The week-176 findings suggest that improvement in predicted cardiovascular risk can persist during continued tirzepatide treatment rather than appearing only during the first year of weight loss.
Should cardiovascular risk be monitored separately from body weight?
Yes. Weight is only one component of obesity-related health. Depending on the patient, useful measures may include blood pressure, lipid levels, glucose or A1c, sleep-apnea status, physical function, and other cardiovascular or metabolic risk factors. Treatment goals should be individualized.
Related BeLite Resources
How BeLite Can Help
At BeLite Medical Center, obesity treatment is approached as long-term medical care. Medication selection is individualized, and treatment response can be considered in the context of weight, side effects, cardiovascular and metabolic risk factors, nutrition, exercise, and the patient’s overall medical history.
Visit BeLite Medical Center to learn more or schedule a free consultation.
References
Predicted 10-year cardiovascular disease risk reduction with tirzepatide use over 3 years for primary prevention of cardiovascular disease in obesity. European Journal of Preventive Cardiology. Published August 10, 2026.
BeLite can help patients translate emerging obesity-medicine evidence into an individualized plan that considers efficacy, tolerability, nutrition, muscle preservation, long-term maintenance, and access.BeLite Medical Center has provided physician-supervised medical weight management in Fairfax, Virginia since 1995. Our clinic offers in-person medical supervision — with the ability to adjust medications and monitor your progress in real time — that fully virtual services cannot match.Booking appointments is simple with our online scheduling portal, available 24/7. You can also call or text us at (703) 359-9200, or email belitemed@gmail.com. We offer free consultations for new patients — if you choose not to enroll, there is no charge. We serve patients across Virginia, Maryland, Washington D.C., the DMV area, Pennsylvania, and West Virginia. Patients do not sign treatment contracts and can stop coming at any time
Medical Disclaimer
This blog post is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to substitute for consultation with a licensed healthcare provider. Readers should not use this information to diagnose or treat a medical or health condition without consulting an appropriately qualified healthcare professional. Any reliance on the information in this blog is at the readers own risk. Individual weight loss results vary based on personal health status and adherence to medical advice. No doctor-patient relationship is created by accessing or reading this content.
Reviewed by Richard Rothman, MD, PhD — Medical Director, BeLite Medical Center.
